Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation

od Castells, M, Milhas, D, Gandy, C, Thibault, B, Rafii, A, Delord, J-P, Couderc, B
Izdano 2013

Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment

od Betrian, S, Ysebaert, L, Heider, K H, Delord, J P, Fournié, J J, Quillet-Mary, A
Izdano u Blood Cancer J (2016)

The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non–small-cell lung cancer: a real-life retrospective study

od Dupont, R., Bérard, E., Puisset, F., Comont, T., Delord, J.-P., Guimbaud, R., Meyer, N., Mazieres, J., Alric, L.
Izdano u Oncoimmunology (2019)

Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience.

od Llombart-Cussac, A., Pivot, X., Contesso, G., Rhor-Alvarado, A., Delord, J. P., Spielmann, M., Türsz, T., Le Cesne, A.
Izdano 1998

Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model

od Delord, J-P, Quideau, S, Rochaix, P, Caselles, O, Couderc, B, Hennebelle, I, Courbon, F, Canal, P, Allal, B C
Izdano 2010

Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation

od Balin-Gauthier, D, Delord, J-P, Pillaire, M-J, Rochaix, P, Hoffman, J-S, Bugat, R, Cazaux, C, Canal, P, Allal, B C
Izdano 2008

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients

od Rouits, E, Charasson, V, Pétain, A, Boisdron-Celle, M, Delord, J-P, Fonck, M, Laurand, A, Poirier, A-L, Morel, A, Chatelut, E, Robert, J, Gamelin, E
Izdano 2008

Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer

od Delord, J-P, Bennouna, J, Artru, P, Perrier, H, Husseini, F, Desseigne, F, François, E, Faroux, R, Smith, D, Piedbois, P, Naman, H, Douillard, J Y, Bugat, R
Izdano 2007

A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies

od Spreafico, A, Delord, J-P, De Mattos-Arruda, L, Berge, Y, Rodon, J, Cottura, E, Bedard, P L, Akimov, M, Lu, H, Pain, S, Kaag, A, Siu, L L, Cortes, J
Izdano u Br J Cancer (2015)

Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck

od Mesía, R., Rivera, F., Kawecki, A., Rottey, S., Hitt, R., Kienzer, H., Cupissol, D., De Raucourt, D., Benasso, M., Koralewski, P., Delord, J.-P., Bokemeyer, C., Curran, D., Gross, A., Vermorken, J. B.
Izdano 2010

Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial

od Melichar, B, Casado, E, Bridgewater, J, Bennouna, J, Campone, M, Vitek, P, Delord, J-P, Cerman, J, Salazar, R, Dvorak, J, Sguotti, C, Urban, P, Viraswami-Appanna, K, Tan, E, Tabernero, J
Izdano 2011

A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours

od Delord, J P, Pierga, J Y, Dieras, V, Bertheault-Cvitkovic, F, Turpin, F L, Lokiec, F, Lochon, I, Chatelut, E, Canal, P, Guimbaud, R, Mery-Mignard, D, Cornen, X, Mouri, Z, Bugat, R
Izdano 2005

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/I...

od Vermorken, J. B., Peyrade, F., Krauss, J., Mesía, R., Remenar, E., Gauler, T. C., Keilholz, U., Delord, J. P., Schafhausen, P., Erfán, J., Brümmendorf, T. H., Iglesias, L., Bethe, U., Hicking, C., Clement, P. M.
Izdano 2014

Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group

od Khalifa, J., Ouali, M., Chaltiel, L., Le Guellec, S., Le Cesne, A., Blay, J-Y, Cousin, P., Chaigneau, L., Bompas, E., Piperno-Neumann, S., Bui-Nguyen, B., Rios, M., Delord, J-P, Penel, N., Chevreau, C.
Izdano u BMC Cancer (2015)

An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable he...

od Temam, S, Spicer, J, Farzaneh, F, Soria, J C, Oppenheim, D, McGurk, M, Hollebecque, A, Sarini, J, Hussain, K, Soehrman Brossard, S, Manenti, L, Evers, S, Delmar, P, Di Scala, L, Mancao, C, Feuerhake, F, Andries, L, Ott, M G, Passioukov, A, Delord, J P
Izdano u Ann Oncol (2017)

Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the...

od Le Tourneau, C, Paoletti, X, Servant, N, Bièche, I, Gentien, D, Rio Frio, T, Vincent-Salomon, A, Servois, V, Romejon, J, Mariani, O, Bernard, V, Huppe, P, Pierron, G, Mulot, F, Callens, C, Wong, J, Mauborgne, C, Rouleau, E, Reyes, C, Henry, E, Leroy, Q, Gestraud, P, La Rosa, P, Escalup, L, Mitry, E, Trédan, O, Delord, J-P, Campone, M, Goncalves, A, Isambert, N, Gavoille, C, Kamal, M
Izdano 2014

Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France

od Blay, J.Y., Boucher, S., Le Vu, B., Cropet, C., Chabaud, S., Perol, D., Barranger, E., Campone, M., Conroy, T., Coutant, C., De Crevoisier, R., Debreuve-Theresette, A., Delord, J.P., Fumoleau, P., Gentil, J., Gomez, F., Guerin, O., Jaffré, A., Lartigau, E., Lemoine, C., Mahe, M.A., Mahon, F.X., Mathieu-Daude, H., Merrouche, Y., Penault-Llorca, F., Pivot, X., Soria, J.C., Thomas, G., Vera, P., Vermeulin, T., Viens, P., Ychou, M., Beaupere, S.
Izdano u ESMO Open (2021)